Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Our innovative AI engine is revolutionizing the drug discovery process, enabling the creation of superior medications at an accelerated pace. The breakthroughs we achieve contribute to the development of medicines more efficiently and effectively. Our portfolio of AI-driven discoveries encompasses entirely owned and collaboratively developed pipeline assets, supported by leading investors in the industry. Atomwise has engineered a cutting-edge machine-learning discovery platform that merges the capabilities of convolutional neural networks with extensive chemical libraries to identify new small-molecule treatments. The key to transforming drug discovery through AI lies in our talented team. We are committed to enhancing our AI platform and leveraging it to revolutionize the discovery of small molecule drugs. It is essential that we confront the most daunting and seemingly insurmountable targets, streamlining the entire drug discovery process to provide developers with increased opportunities for success. Enhanced computational efficiency allows us to screen trillions of compounds virtually, significantly boosting the chances of finding viable solutions. Our impressive model accuracy has successfully addressed the persistent issue of false positives, underscoring the reliability of our approach. Ultimately, our dedication to innovation and excellence sets us apart in the quest for breakthrough therapies.
Description
DrugCard is an AI-powered pharmacovigilance platform designed to help pharmaceutical companies, CROs, and drug safety teams automate routine PV processes and manage safety information more efficiently. The platform brings together global and local literature monitoring, regulatory intelligence, and adverse event management in one connected workflow.
DrugCard supports PV teams in identifying relevant safety information faster, reducing manual screening workload, and maintaining transparent, audit-ready processes. Its literature monitoring module covers 121+ countries, 2,200+ local medical sources, and 100+ languages, including both global databases such as PubMed and local, non-indexed medical journals.
The platform uses AI to support article pre-assessment, generate structured summaries, highlight relevant keywords, assist with translations, and help users prioritize publications that may require safety review. DrugCard also provides configurable workflows, automated notifications, reporting tools, QC functionality, audit trails, and case creation from literature.
With additional modules for Regulatory Intelligence and Adverse Event Database management, DrugCard helps organizations track health authority updates, centralize safety data, support E2B workflows, and improve overall pharmacovigilance operations. Built for MAHs, QPPVs, LQPPVs, CROs, regulatory teams, and PV professionals, DrugCard combines automation with human expert oversight to support compliant, scalable, and reliable drug safety management.
API Access
Has API
API Access
Has API
Integrations
No details available.
Integrations
No details available.
Pricing Details
No price information available.
Free Trial
Free Version
Pricing Details
individual
Free Trial
Free Version
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Vendor Details
Company Name
Atomwise
Founded
2012
Country
United States
Website
www.atomwise.com
Vendor Details
Company Name
DrugCard
Founded
2021
Country
Estonia
Website
drug-card.io